Denali Therapeutics (NASDAQ:DNLI) Receives Buy Rating from HC Wainwright

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $90.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 204.57% from the company’s current price.

Several other analysts have also recently weighed in on the stock. Jefferies Financial Group upped their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Bank of America lifted their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. JPMorgan Chase & Co. decreased their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Wedbush cut their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

Denali Therapeutics Trading Up 6.9 %

DNLI opened at $29.55 on Thursday. The firm’s fifty day moving average price is $27.57 and its two-hundred day moving average price is $23.36. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13.

Insider Buying and Selling

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the transaction, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Large investors have recently made changes to their positions in the company. Victory Capital Management Inc. grew its stake in Denali Therapeutics by 163.7% in the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after acquiring an additional 24,767 shares during the period. Assetmark Inc. lifted its holdings in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. AIA Group Ltd increased its stake in Denali Therapeutics by 7.9% during the 3rd quarter. AIA Group Ltd now owns 74,815 shares of the company’s stock worth $2,179,000 after purchasing an additional 5,471 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after buying an additional 149,939 shares during the period. Finally, VELA Investment Management LLC bought a new position in Denali Therapeutics in the third quarter valued at approximately $455,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.